Abbott launches HPV diagnostic in Canada; Biosensors snags drug-eluting balloon license;

@FierceMedDev: Smiths eyes $3B-plus medical biz sale. Report | Follow @FierceMedDev

@DamianFierce: If you're a hospital and can prove Covidien's oximeters beat Masimo's, you may be due $1 million. Story | Follow @DamianFierce

@MichaelGFierce: Roche, Cook help launch public-private Indiana research institute. Article | Follow @MichaelGFierce

> Abbott Laboratories ($ABT) won Canadian approval for its RealTime molecular diagnostic for HPV, which has been available overseas since 2008 but lacks the FDA's blessing. News

> Singapore's Biosensors International has licensed a drug-eluting balloon from German devicemaker Eurocor, bolstering the company's vascular offerings. Release

> Ames Technology, a spinout of Oregon Health & Science University, won FDA clearance for its robotic muscle and joint rehabilitation device. Story

> Cheap, inflatable leg wraps could help save the lives of stroke patients, according to a study. Report

> The University of Minnesota has opened the doors to its new state-of-the-art medical device lab, designed to train the biomedical engineers of the future for the state's bustling industry. Article

> Devicemaker Oncologix is negotiating with two healthcare service providers to expand adoption of its products. More

> GE Healthcare ($GE) won FDA clearance for its Brivo Plus C-arm, designed for surgical imaging. Item

Biotech News

@FierceBiotech: ICYMI: Top 10 experimental cancer drugs - 2013. Special report | Follow @FierceBiotech

@JohnCFierce: Discounting wins NICE recommendation for Eylea, another score for Regeneron/Bayer. Report | Follow @JohnCFierce

@RyanMFierce: Satori Pharmaceuticals shuts down after failure of Alzheimer's drug. News | Follow @RyanMFierce

@EmilyMFierce: Japan launches public-private consortium to hunt for new drugs for infectious diseases. Item | Follow @EmilyMFierce

> Lung cancer spotlighted as prime target for new immunotherapies. Article

> FDA snubs Endo's testosterone drug over REMS concerns. News

> Epizyme scores latest biotech IPO victory to advance cancer pipeline. Story

Pharma News

@FiercePharma: ICYMI: Bristol-Myers, AstraZeneca win turnabout at NICE for Forxiga. Diabetes med now backed in some regimens. More | Follow @FiercePharma

@EricPFierce: Will Hospira never learn? FDA warning letter says some problems at India plant same as those recently noted at Rocky Mount. Report | Follow @EricPFierce

@CarlyHFierce: | Follow @CarlyHFierce

> Feud at FDA as staffer's safety review bucks agency line. Story

> Outspoken doctor's pancreas study prompted FDA's new diabetes-drug probe. More

> Serbia's Galenika remains a wallflower with only Valeant in pursuit. Article